Accordingly, targeted pharmacological therapies, such as metreleptin for patients carrying biallelic LEP variants and setmelanotide for patients with biallelic LEPR, POMC, and PCSK1 variants, are available for selected monogenic obesity forms [5–7]. The gene discussed is LEPR; the disease is obesity disorder.